INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES
-
![three robots, futeriistic production, automation-GettyImages-691214916]( "3 Strategies For A Successful Journey Toward Cell And Gene Therapy Commercialization")
3 Strategies For A Successful Journey Toward Cell And Gene Therapy CommercializationCTMC's Amy Hay provides 3 recommendations for teams developing cell and gene therapies, from clinical research through commercialization.
-
![GettyImages-1027139762-test-lab-testing]( "Gene Therapy Solutions: From Discovery To Commercialization")
Gene Therapy Solutions: From Discovery To CommercializationLearn how advanced technologies and methodologies are driving progress in gene therapy, enabling safer and more effective treatments for rare and complex diseases.
-
![GettyImages-1869998960 patient, doctor, clincial trial]( "Implementing Complex Ordering Workflows Has Never Been Easier")
Implementing Complex Ordering Workflows Has Never Been EasierGain valuable program oversight with real-time monitoring and reporting. Stay informed and in control with comprehensive insights into your cell and gene therapy programs.
-
![InspiroGene - bridging the gap]( "Your Ally For Bringing CGTs From Discovery To Delivery")
Your Ally For Bringing CGTs From Discovery To DeliveryBridging the divide between pioneering Cell and Gene Therapy and patient reality. Learn how focused strategies are empowering Biopharma to deliver life-altering treatments with greater speed and efficiency.
-
![23_12_CGPodcast_1280x720_Ep102]( "Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D.")
Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D.In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a developer of autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases.
-
![GettyImages-2067042854-DNA-strand-building-3d]( "Commercializing Your First CGT: Five Best Practices For Planning")
Commercializing Your First CGT: Five Best Practices For PlanningFrom patient identification to reimbursement, commercializing cell and gene therapies is uniquely challenging. Learn five best practices to ensure your innovative CGT reaches the patients who need it.
-
![GettyImages-1480558197 Business Corporate Team Meeting]( "Enabling Market Access As CGTs Reach More Patients")
Enabling Market Access As CGTs Reach More PatientsBringing potentially curative cell and gene therapies to more patients requires a focused approach to market access. Discover essential insights into payer dynamics, pricing innovations, and treatment evolution.
-
![23_12_CGPodcast_1280x720_Ep100]( "Rethinking CGT Biotech Growth & Investment with Audrey Greenberg")
Rethinking CGT Biotech Growth & Investment with Audrey GreenbergOn the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures.
-
![Filling a syringe-GettyImages-1413526755]( "4 Key Solid Tumor Therapy Objectives iPSCs Can Help Achieve")
4 Key Solid Tumor Therapy Objectives iPSCs Can Help AchieveInduced pluripotent stem cells offer some key biologic, technical, and financial advantages over more established PBMC-derived therapies.
-
![GettyImages-1311494510-vaccine-bottle-needle]( "Indian Biosimilar Companies Are Poised To Succeed In The Global Market")
Indian Biosimilar Companies Are Poised To Succeed In The Global MarketFor Indian biosimilar developers looking to capitalize on the upcoming patent cliff, it is vital to play to your strengths and identify strategies for breaking into competitive regulatory markets.
